Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Data
23 mars 2020 15h00 HE
|
Reports and Data
New York, March 23, 2020 (GLOBE NEWSWIRE) -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a CAGR of...
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
17 avr. 2019 08h00 HE
|
Celsion CORP
Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox® Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...
Nanobiotix annonce son plan d’enregistrement clinique dans les cancers de la Tête et du Cou avec NBTXR3 aux Etats-Unis à la suite du retour de la FDA
26 mars 2019 03h00 HE
|
NANOBIOTIX
Préparation d’une étude clinique évènementielle, randomisée et évaluant la survie globale (SG) aux États-UnisLe retour (pre-IND) de la Food and Drug Administration (FDA) permet de clarifier l’approche...
Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
26 mars 2019 03h00 HE
|
NANOBIOTIX
Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United StatesPre-IND feedback from US Food and Drug Administration (FDA) provides clarity to...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
24 avr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
19 avr. 2018 06h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...